SEC Form 4 · accession 0001209191-18-014684
NEOGENOMICS INC · NEO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kathryn B McKenzie
Officer — Principal Accounting Officer
Period of report
Feb 26, 2018
Accepted (ET)
Feb 28, 2018 · 6:59 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001077183
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $8.03 | Feb 26, 2018 | A | 48,000 | A | Feb 26, 2019 | Feb 26, 2023 | Common Stock | 48,000 | 48,000 | D |
| Stock Option (Right to Buy)F1 | $9.52 | holding | — | — | — | Oct 17, 2018 | Oct 17, 2022 | Common Stock | 25,000 | 25,000 | D |
Explanation of responses
- F1On October 18, 2017, Ms. McKenzie was granted an option to purchase 25,000 shares of NeoGenomics, Inc. common stock. The options vest ratably over the first three anniversary dates of the grant date.
- F2On February 26, 2018, Ms. McKenzie was granted an option to purchase 48,000 shares of NeoGenomics, Inc. common stock. The options vest ratably over the first three anniversary dates of the grant date.